Skip to main content
. Author manuscript; available in PMC: 2017 Oct 1.
Published in final edited form as: Neurochem Res. 2016 Dec 28;42(4):1202–1210. doi: 10.1007/s11064-016-2157-9

Fig. 1.

Fig. 1

Effects of blockade of mAChRs on ERK1/2 phosphorylation in the rat striatum and mPFC. a Effects of the mAChR antagonist scopolamine on ERK1/2 phosphorylation in the CPu. b Effects of scopolamine on ERK1/2 phosphorylation in the NAc. c Effects of scopolamine on ERK1/2 phosphorylation in the mPFC. Representative immunoblots are shown to the left of the quantified data. Two bands were typically observed in pERK1/2 and ERK1/2 immunoblots (upper bands: pERK1 and ERK1 at 44 kDa; lower bands: pERK2 and ERK2 at 42 kDa). Note that scopolamine time-dependently increased pERK2 levels in the CPu, NAc, and mPFC. Rats were treated with an i.p. injection of scopolamine (5 mg/kg) and were sacrificed at different time points (7.5, 15, or 30 min) after drug injection for Western blot analysis. Data are presented as means ± SEM (n = 5 per group). *p < 0.05 versus saline (0 min)